This dual evaluation in metastatic sites may eventually improve the stratification of advanced breast cancer patients for immunotherapy given that CD8+ T cells must be present within the tumor bed for an effective immunotherapy response [10]. The gene discussed is CD8A; the disease is neoplasm.